Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Autoimmunity BioSolutions has raised $1.0M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Autoimmunity BioSolutions's investors include Alexandria Venture Investments, Eos BioInnovation, NewTech Investment Holdings, Independent Capital Management, Inc., Elmsted Partners LLC.
Autoimmunity BioSolutions is headquartered in Houston, United States.
Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Autoimmunity BioSolutions is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autoimmunity BioSolutions — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/autoimmunity-biosolutions. Accessed July 30, 2026.
VCBacked. (2026). Autoimmunity BioSolutions — Funding & Investors. Retrieved July 30, 2026, from https://www.vcbacked.co/company/autoimmunity-biosolutions
{{cite web |title=Autoimmunity BioSolutions — Funding & Investors |url=https://www.vcbacked.co/company/autoimmunity-biosolutions |website=VCBacked |access-date=July 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated